-+ 0.00%
-+ 0.00%
-+ 0.00%

BioArctic: Leqembi Iqlik Becomes Available in US for Initiation Therapy for Early Alzheimer's Disease

MT Newswires·08/24/2026 09:23:42
Listen to the news
09:23 AM EDT, 08/24/2026 (MT Newswires) -- BioArctic (BIOA-B.ST) partner Eisai launched lecanemab-irmb subcutaneous injection, or Leqembi Iqlik, in the US for initiation treatment for early Alzheimer's disease. The Swedish biopharmaceutical company said Monday the drug, administered through an autoinjector, is the first anti-amyloid treatment offering at-home dosing for initiation and maintenance. The drug received the US Food and Drug Administration's approval on July 13.